Evidence map›Paper›PMID 41002553›Full record

ArticleCurrent oncology (Toronto, Ont.)2025

Real-World Selection of Patients for Allogeneic HCT at a Single Centre: Lack of a Suitable Donor and Other Reasons for Not Proceeding.

Madeline Monaghan, An Duong, Kalina Abrol, Trang Doan, Carolina Cieniak, Harold Atkins, Natasha Kekre, Ashish Masurekar, Ram Vasudevan Nampoothiri, Santhosh Thyagu and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Current oncology (Toronto, Ont.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Madeline MonaghanFaculty of Medicine, University of Ottawa, Ottawa, ON K1H 8M5, Canada.
An DuongCancer Research Program, Ottawa Hospital Research Institute, Ottawa, ON K1H 8L6, Canada.
Kalina AbrolTransplantation & Cellular Therapy Program, Department of Medicine (Hematology), The Ottawa Hospital, Ottawa, ON K1H 8L6, Canada.
Trang DoanTransplantation & Cellular Therapy Program, Department of Medicine (Hematology), The Ottawa Hospital, Ottawa, ON K1H 8L6, Canada.
Carolina CieniakTransplantation & Cellular Therapy Program, Department of Medicine (Hematology), The Ottawa Hospital, Ottawa, ON K1H 8L6, Canada.
Harold AtkinsFaculty of Medicine, University of Ottawa, Ottawa, ON K1H 8M5, Canada.ORCID 0000-0002-6168-3939
Natasha KekreFaculty of Medicine, University of Ottawa, Ottawa, ON K1H 8M5, Canada.
Ashish MasurekarFaculty of Medicine, University of Ottawa, Ottawa, ON K1H 8M5, Canada.
Ram Vasudevan NampoothiriFaculty of Medicine, University of Ottawa, Ottawa, ON K1H 8M5, Canada.
Santhosh ThyaguFaculty of Medicine, University of Ottawa, Ottawa, ON K1H 8M5, Canada.
Christopher N BredesonFaculty of Medicine, University of Ottawa, Ottawa, ON K1H 8M5, Canada.
Michael KennahFaculty of Medicine, University of Ottawa, Ottawa, ON K1H 8M5, Canada.ORCID 0009-0005-5920-2736
David S AllanFaculty of Medicine, University of Ottawa, Ottawa, ON K1H 8M5, Canada.ORCID 0000-0003-3261-8289

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The reasons why patients cannot proceed with HCT, including cases where no suitable donor is identified, remain poorly described. We reviewed all referrals for allogeneic HCT to our programme between 1 January 2019 and 31 December 2023. Of 880 patients referred for allogeneic HCT, 494 (61.8%) proceeded to transplant (mean 52 ± 14.8 years, 61.5% male) using HLA-matched unrelated (64.2%) or related (19.4%) donors and HLA-mismatched (13%) or haploidentical (3%) donors. Of patients that did not proceed with HCT (386, 38.2%), disease-related causes (54.2%), patient preference (15.8%), and significant patient comorbidity (11.4%) were the most common reasons. Eleven patients (2.9% of transplants that did not proceed; 1.3% of all referrals) lacked a suitable donor and had HLA phenotypes most associated with Caucasian (six patients, 55%), First Nations, Inuit or Metis (two patients, 18%), Black African, Caribbean or African American (one patient, 9%), Asian or Pacific Islander (9%), or unknown ethnicity (one patient, 9%). Very few patients were unable to proceed with transplant due to lack of a suitable donor; however, those cases are overrepresented by non-Caucasian ethnicity relative to the population.

Indexed as

Hematopoietic Stem Cell TransplantationPatient SelectionTissue DonorsAdultAgedFemaleHumansMaleMiddle AgedTransplantation, Homologousallogeneicco-morbiditydisease progressiondonorhematopoietic cell transplantno donorsearchtoxicity

Identifiers

PMID41002553
PMCPMC12468098

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.